C
NVO

CEDRUS’s Novo Nordisk NVO Stock Holding History

CEDRUS’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$324K Sell
2,719
-119
-4% -$15.9K 0.12% 133
2024
Q2 		$405K Buy
2,838
+186
+7% +$24.6K 0.2% 92
2024
Q1 		$341K Buy
+2,652
New +$316K 0.19% 106

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CEDRUS's NVO Position: Q3 2024 in Review

CEDRUS reduced its Novo Nordisk (NVO) stake by 4.2% in Q3 2024, selling an estimated $15.9K and leaving 2,719 shares worth $324K. The position accounts for 0.12% of the portfolio, ranked #133.

CEDRUS first reported a position in NVO in Q1 2024 and has held it in 3 quarters since. The position peaked at $405K in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • CEDRUS held 2,719 shares of Novo Nordisk worth $324K as of Q3 2024.
  • CEDRUS sold 119 Novo Nordisk shares in Q3 2024, an estimated $15.9K.
  • Novo Nordisk made up 0.12% of CEDRUS's portfolio in Q3 2024, its #133 holding.
  • CEDRUS first reported a position in Novo Nordisk in Q1 2024 and has held it in 3 quarters since.
  • CEDRUS's Novo Nordisk position peaked at $405K in Q2 2024.
  • 1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on CEDRUS's 13F filing for Q3 2024, filed 18 Oct 2024.